ALFA Finder| Revenue growth | 19% YoY for FY26 to ₹904 crores. |
|---|---|
| Margins | Adjusted EBITDA margin at 13.4% for FY26. |
| Demand visibility | Strong trust with customers; growing relevance in CDMO space. |
| Management confidence | High; citing 13 consecutive quarters of record revenue. |
Growth
FY26 Revenue: ₹904cr (+19%); Q4 Revenue: ₹238cr (+18%). FY26 Adjusted EBITDA: ₹121cr (13.4%); PAT: ₹83cr (9.2%).
Outlook
Plant 6 commercialization by H1 FY27; targeting ₹1,000cr+ revenue capacity; expanding injectables and export vertical growth.
Risks
Regulatory intensity increasing; supply disruptions/API price hikes due to West Asia crisis; loss of codeine-based syrup business.
Earnings Call filed with BSE, NSE: WINDLAS. Summary written with AI assistance from the document.
Windlas Biotech Ltd: key numbers
- Share price
- ₹998.85
- Market cap
- ₹2,096 Cr
- Revenue (annual)
- ₹904.1 Cr
- Net profit (annual)
- ₹66.44 Cr
- P/E (TTM)
- 31.4×Sector 43.8×
- Promoter holding
- 63.31%+0.00% QoQ
- FII holding
- 2.09%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Windlas Biotech Ltd
All →Windlas Biotech Management Change
Windlass Biotech reports Mr. Ashok Kumar Windlass ceased as Executive Director, resigning for succession planning, effective 5 November 2026. He moves to Founder President, and Hitesh Windlass becomes Managing Director.
Windlas Biotech Results Update
Windlas Biotech reported H1 FY27 revenue of Rs 512 crore, up 18% YoY. Adjusted PAT rose 33% to Rs 50 crore for the half year.
Windlas Biotech Investor Presentation: Key Takeaways
H1FY27 revenue Rs 512 Cr (+18%), adj. PAT Rs 50 Cr (+33%, 9.7% margin); reported PAT flat at Rs 36 Cr on ESOP charges. CDMO-led growth; Plant-6 commercialised.
Windlas Biotech Q2 FY27 Results: Net Profit ₹18.1 Cr, Up 1.7% YoY
Windlas Biotech Ltd reported revenue from operations of ₹263.9 Cr (+18.7% YoY) and net profit of ₹18.1 Cr (+1.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹18.1 Cr · +1.7% YoY
Windlas Biotech Adverse Business Impact
Windlas Biotech disclosed a cyber security incident on 30 October 2026. It states no material impact on core operations, finances or business continuity.
Windlas Biotech Board Meeting Date
Windlas Biotech intimated that its Board meeting is scheduled for 5 November 2026 to consider unaudited standalone results for Q1 FY27. No monetary figure is disclosed in this advance notice.